Actos Sales Grow On Avandia's Woes, Takeda Reports
This article was originally published in PharmAsia News
Executive Summary
U.S. sales of the type 2 diabetes therapy Actos (pioglitazone) were up $117 million or 19.2 percent year over year in the first quarter of 2007, Takeda General Manager of Finance and Accounting Hiroshi Takahara reported during the company's first-quarter 2007 earnings call July 31
You may also be interested in...
Avandia Should Stay On Market, Committee Says
Joint advisory committee concludes, however, that the thiazolidinedione raises cardiovascular risk.
Avandia Revenues Sink Under Safety Attack
Sales of rosiglitazone were hit the hardest in the U.S., falling 31 percent, GSK reports days ahead of an FDA advisory committee meeting.
Novartis To Resubmit Galvus In Mid-2009
Safety study responding to FDA’s “approvable” letter for the type 2 diabetes therapy will take months, not weeks; firm also faces delay for oncologic Tasigna.